1 Letterman Dr
3 articles with Sonoma BioTherapeutics
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases
Sonoma Biotherapeutics, a privately held company developing regulatory T-cell therapies for autoimmune and degenerative diseases, announced that it has raised an additional $30 million from investors in its Series A financing, bringing the total to $70 million.
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
Company founded by four pioneers of Treg cell biology and cell therapy and financed by a syndicate of leading biotech investors
2/6/2020Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.